Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine vs escitalopram for subjective sleep improvement in major depressive disorder
2006-006540-54Phase 3Completed
- Sponsor
- Servier
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Global satisfaction on sleep score. Started Apr 2007; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-006540-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006540-54.